Reports
Sale
Atopic Dermatitis Market Size, Share, Analysis, Forecast: By Drug Class: PDE4 Inhibitors, Biologics, Others; By Route of Administration: Oral, Topical, Injectables; Regional Analysis; Market Dynamics: Market Drivers and Constraints, SWOT Analysis, Porter’s Five Forces Model, Key Demand Indicators; Supplier Landscape; 2024-2032
Atopic Dermatitis Market Outlook
The atopic dermatitis market size was valued at USD 9.33 billion in 2023, driven by the rising prevalence of dermatological skin disorders across 8 major markets. The market is expected to grow at a CAGR of 15.10% during the forecast period of 2024-2032, with the values likely to rise from USD 10.73 billion in 2024 to USD 33.07 billion by 2032.
Atopic Dermatitis Market Overview
Atopic dermatitis (AD) is a skin disease characterized by itchy, dry, and inflamed skin. It is the most common type of skin disease. The condition affects approximately 204.05 million people globally, with a prevalence rate of 2.6%. Females are more likely to suffer from AD than males, with a prevalence rate of 2.8% compared to males (2.4%). The rising prevalence of the disease is expected to augment the market size in the forecast period.
The atopic dermatitis market growth is also driven by the surge in approvals from health regulatory agencies. In December 2023 , the United States Food and Drugs Administration (FDA) approved a human monoclonal antibody known as tralokinumab-ldrm (Adbry) for children (aged 12 to 17 years old) affected from atopic dermatitis. The medication, developed by a multinational Danish pharmaceutical company LEO Pharma A/S, is the first FDA-approved interleukin (IL)-13 inhibitor that targets the main source of the skin disease’s symptoms. Such advancements in the treatment landscape of atopic dermatitis are likely to fuel the market growth.
The atopic dermatitis market demand is also pushed by the development of novel medications and effective treatment solutions. The rising awareness among patients and increasing healthcare expenditure will further aid the market growth in the coming years.
Atopic Dermatitis Market Segmentation
Market Breakup by Drug Class
- PDE4 Inhibitors
- Biologics
- Others
The market is segmented by drug class into PDE4 inhibitors, biologics, and others. PDE4 inhibitors target inflammation and reduce symptoms like itching and redness. On the other hand, biologics (used in severe cases), modulate the immune system response by blocking specific proteins.
Market Breakup by Route of Administration
- Oral
- Topical
- Injectables
The atopic dermatitis market share is segmented by route of administration into oral, topical, and injectables. This segmentation reflects the different methods of medication administration available for treating atopic dermatitis.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
The market report covers 8 major markets poised to witness significant growth in the forecast period. The region-based segmentation of the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, along with China. North America is leading the market, owing to heightened awareness among patients regarding treatment options. The presence of an robust healthcare system, and the increased prevalence of atopic dermatitis in the region.
Atopic Dermatitis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AbbVie Inc.
- Astellas Pharma Inc.
- Bayer AG
- Bristol Myers Squibb Inc.
- Eli Lilly and Company Inc.
- Galderma Inc.
- Pfizer Inc.
- Novartis AG
- Viatris Inc.
- Sanofi SA
- Regeneron Pharmaceuticals, Inc.
- Leo Pharma, Inc.
- Incyte Corporation, Inc.
- Arcutis Biotherapeutics, Inc.
- Asana Biosciences, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Atopic Dermatitis Market Report
- How will the market landscape evolve in the coming years?
- What are the major market trends influencing the market?
- What are the major drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What is the prevalence of atopic dermatitis? How is it distributed across different demographics?
- How do factors such as the rising prevalence of atopic dermatitis impact market growth?
- What are the different types of atopic dermatitis treatments available in the market?
- What are the latest advancements in atopic dermatitis drug research and development?
- Which drugs currently under clinical trials are poised to elevate the atopic dermatitis market size in forecast period?
- What are the major drug approvals to manage atopic dermatitis during the historical period?
- Which segment has the major impact on the market size?
- What investments and funding are driving research and development in the market?
- Which companies are involved in developing most advanced treatment options for patients?
- What are the key strategies adopted by leading pharmaceutical companies to gain market share?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Atopic Dermatitis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Atopic Dermatitis Epidemiology Analysis – 8MM
5.1 8MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.3.1 Germany Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.3.2 France Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.3.3 Italy Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.3.4 Spain Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.4 Japan Atopic Dermatitis Epidemiology Forecast (2017-2032)
5.5 China Atopic Dermatitis Epidemiology Forecast (2017-2032)
6 Atopic Dermatitis Market Overview – 8MM
6.1 Atopic Dermatitis Market Historical Value (2017-2023)
6.2 Atopic Dermatitis Market Forecast Value (2024-2032)
7 Atopic Dermatitis Market Landscape – 8MM
7.1 Atopic Dermatitis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Atopic Dermatitis Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Route of Administration
8 Atopic Dermatitis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Atopic Dermatitis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Atopic Dermatitis Market Segmentation – 8MM
11.1 Atopic Dermatitis Market by Drug Class
11.1.1 Market Overview
11.1.2 PDE4 Inhibitors
11.1.3 Biologics
11.1.4 Others
11.2 Atopic Dermatitis Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Topical
11.2.4 Injectables
11.3 Atopic Dermatitis Market by Region
11.3.1 Market Overview
11.3.2 United States
11.3.3 EU-4 and the United Kingdom
11.3.3.1 Germany
11.3.3.2 France
11.3.3.3 Italy
11.3.3.4 Spain
11.3.3.5 United Kingdom
11.3.4 Japan
11.3.5 China
12 United States Atopic Dermatitis Market
12.1 Atopic Dermatitis Market Historical Value (2017-2023)
12.2 Atopic Dermatitis Market Forecast Value (2024-2032)
12.3 Atopic Dermatitis Market by Drug Class
12.4 Atopic Dermatitis Market by Route of Administration
13 EU-4 and United Kingdom Atopic Dermatitis Market
13.1 Atopic Dermatitis Market Historical Value (2017-2023)
13.2 Atopic Dermatitis Market Forecast Value (2024-2032)
13.3 Germany Atopic Dermatitis Market Overview
13.3.1 Atopic Dermatitis Market by Drug Class
13.3.2 Atopic Dermatitis Market by Route of Administration
13.4 France Atopic Dermatitis Market Overview
13.4.1 Atopic Dermatitis Market by Drug Class
13.4.2 Atopic Dermatitis Market by Route of Administration
13.5 Italy Atopic Dermatitis Market Overview
13.5.1 Atopic Dermatitis Market by Drug Class
13.5.2 Atopic Dermatitis Market by Route of Administration
13.6 Spain Atopic Dermatitis Market Overview
13.6.1 Atopic Dermatitis Market by Drug Class
13.6.2 Atopic Dermatitis Market by Route of Administration
13.7 United Kingdom Atopic Dermatitis Market Overview
13.7.1 Atopic Dermatitis Market by Drug Class
13.7.2 Atopic Dermatitis Market by Route of Administration
14 Japan Atopic Dermatitis Market
14.1 Atopic Dermatitis Market Historical Value (2017-2023)
14.2 Atopic Dermatitis Market Forecast Value (2024-2032)
14.3 Atopic Dermatitis Market by Drug Class
14.4 Atopic Dermatitis Market by Route of Administration
15 China Atopic Dermatitis Market
15.1 Atopic Dermatitis Market Historical Value (2017-2023)
15.2 Atopic Dermatitis Market Forecast Value (2024-2032)
15.3 Atopic Dermatitis Market by Drug Class
15.4 Atopic Dermatitis Market by Route of Administration
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 JAPAN PMDA
16.1.4 China NMPA
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnerships and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 AbbVie Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Astellas Pharma Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Bayer AG
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Bristol Myers Squibb Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Eli Lilly and Company Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Galderma Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Pfizer Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Novartis AG
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Viatris Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Sanofi SA
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Regeneron Pharmaceuticals, Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Leo Pharma, Inc.
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Incyte Corporation, Inc.
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifictions
22.14 Arcutis Biotherapeutics, Inc.
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 Asana Biosciences, Inc.
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
23 Atopic Dermatitis Market- Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 9.33 billion in 2023 driven by the rising prevalence of dermatological skin disorders across 8 major markets.
The market is anticipated to grow at a CAGR of 15.10% during the forecast period of 2024-2032, likely to reach a market value of USD 33.07 billion by 2032.
The emphasis on developing effective and advanced treatment solutions along with increased healthcare expenditure are fuelling the market demand. Surge in research initiatives by prominent academic institutions also contributes to market demand.
One of the significant trends in the market is the surge in drug approvals from health regulatory agencies such as the FDA. In December 2023, the FDA approved LEO Pharma's, tralokinumab-ldrm (Adbry), a human monoclonal antibody for treating atopic dermatitis in children.
The market is segmented by drug class into PDE4 inhibitors, biologics, and others.
The atopic dermatitis market is segmented by route of administration into oral, topical, and injectables.
The major regions of the market include United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China.
Key players involved in the market are AbbVie Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb Inc., Eli Lilly and Company Inc., Galderma Inc., Pfizer Inc., Novartis AG, Viatris Inc., Sanofi SA, Regeneron Pharmaceuticals, Inc., Leo Pharma, Inc., Incyte Corporation, Inc., Arcutis Biotherapeutics, Inc., and Asana Biosciences, Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER